Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

Open access
Hodi, F. Stephen, Lawrence, Donald, Lezcano, Cecilia, Wu, Xinqi, Zhou, Jun, Sasada, Tetsuro, Zeng, Wanyong, Giobbie-Hurder, Anita, Atkins, Michael B., Ibrahim, Nageatte, Friedlander, Philip, Flaherty, Keith T., Murphy, George F., Rodig, Scott, Velazquez, Elsa F., Mihm, Martin C., Russell, Sara, DiPiro, Pamela J., Yap, Jeffrey T., Ramaiya, Nikhil, Van den Abbeele, Annick D., Gargano, Maria, McDermott, David · 2014 · Cancer Immunology Research

Published version of a preprint

Abstract

Ipilimumab improves survival in advanced melanoma and can induce immune-mediated tumor vasculopathy. Besides promoting angiogenesis, vascular endothelial growth factor (VEGF) suppresses dendritic cell maturation and modulates lymphocyte endothelial trafficking. This study investigated the combination of CTLA4 blockade with ipilimumab and VEGF inhibition with bevacizumab. Patients with metastatic melanoma were treated in four dosing cohorts of ipilimumab (3 or 10 mg/kg) with four doses at 3-week intervals and then every 12 weeks, and bevacizumab (7.5 or 15 mg/kg) every 3 weeks. Forty-six patients were treated. Inflammatory events included giant cell arteritis (n = 1), hepatitis (n = 2), and uveitis (n = 2). On-treatment tumor biopsies revealed activated vessel endothelium with extensive CD8(+) and macrophage cell infiltration. Peripheral blood analyses demonstrated increases in CCR7(+/-)/CD45RO(+) cells and anti-galectin antibodies. Best overall response included 8 partial responses, 22 instances of stable disease, and a disease-control rate of 67.4%. Median survival was 25.1 months. Bevacizumab influences changes in tumor vasculature and immune responses with ipilimumab administration. The combination of bevacizumab and ipilimumab can be safely administered and reveals VEGF-A blockade influences on inflammation, lymphocyte trafficking, and immune regulation. These findings provide a basis for further investigating the dual roles of angiogenic factors in blood vessel formation and immune regulation, as well as future combinations of antiangiogenesis agents and immune checkpoint blockade.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-14-0053

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 601

Metadata

Authors
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., Friedlander, P., Flaherty, K. T., Murphy, G. F., Rodig, S., Velazquez, E. F., Mihm, M. C., Russell, S., DiPiro, P. J., Yap, J. T., Ramaiya, N., Van den Abbeele, A. D., Gargano, M., & McDermott, D.
Affiliations
  • Authors' Affiliations: Departments of 1Medical Oncology,
  • Massachusetts General Hospital (US)
  • University of Pittsburgh Medical Center (US)
  • 2Biostatistics, and
  • Georgetown University (US)
  • Mount Sinai Hospital (US)
  • 5Pathology and
  • 7Tufts University;
  • Brigham and Women's Hospital (US)
  • Dana-Farber Cancer Institute (US)
  • 3Imaging, Dana-Farber Cancer Institute;
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
Hodi, F. Stephen
Venue
Cancer Immunology Research
Published
2014-07-01
Volume
2
Issue
7
Pages
632-642
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2121820529
Cited by
593
References
39
Citations by year
2026: 14 · 2025: 20 · 2024: 32 · 2023: 38 · 2022: 49 · 2021: 70 · 2020: 68 · 2019: 51 · 2018: 59 · 2017: 64 · 2016: 65 · 2015: 47 · 2014: 16
FWCI
30.92
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA158467, R21CA143832, CA143832, 1R012CA158467)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
bevacizumab, ipilimumab, metastatic melanoma, CTLA-4 blockade, VEGF-A inhibition, immune checkpoint blockade, anti-angiogenic therapy, tumor vasculature, lymphocyte migration, CCR7, CD8+ T cells, macrophage infiltration, immune-related adverse events, combination immunotherapy
MeSH terms
Bevacizumab, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Neovascularization, Pathologic, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. https://app.cochat.ai/papers/10.1158/2326-6066.cir-14-0053
The paper
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., Friedlander, P., Flaherty, K. T., Murphy, G. F., Rodig, S., Velazquez, E. F., Mihm, M. C., Russell, S., DiPiro, P. J., Yap, J. T., . . . McDermott, D. (2014). Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-14-0053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.